5i75 › Citations

X-ray structures and mechanism of the human serotonin transporter.

<div class='caption-title'>Function and architecture of the human serotonin transporter</div>
<div class='caption-title'>Antidepressant binding and recognition</div>
<div class='caption-title'>Allosteric site</div>
Coleman JA, Green EM, Gouaux E
OpenAccess logo Nature 532 334-9 (2016)
Related entries: 5i66, 5i6x, 5i6z, 5i71, 5i73, 5i74

Cited: 340 times
EuropePMC logo PMID: 27049939

Abstract

The serotonin transporter (SERT) terminates serotonergic signalling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons. SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signalling. Here we report X-ray crystallographic structures of human SERT at 3.15 Å resolution bound to the antidepressants (S)-citalopram or paroxetine. Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helices 1, 3, 6, 8 and 10, directly blocking serotonin binding. We further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helices 1, 6, 10 and 11. Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand. These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.

Articles - 5i75 mentioned but not cited (6)

  1. X-ray structures and mechanism of the human serotonin transporter. Coleman JA, Green EM, Gouaux E. Nature 532 334-339 (2016)
  2. Multiscale Simulations of Biological Membranes: The Challenge To Understand Biological Phenomena in a Living Substance. Enkavi G, Javanainen M, Kulig W, Róg T, Vattulainen I. Chem Rev 119 5607-5774 (2019)
  3. Conformational dynamics of the human serotonin transporter during substrate and drug binding. Möller IR, Slivacka M, Nielsen AK, Rasmussen SGF, Gether U, Loland CJ, Rand KD. Nat Commun 10 1687 (2019)
  4. Trimerization of dopamine transporter triggered by AIM-100 binding: Molecular mechanism and effect of mutations. Cheng MH, Ponzoni L, Sorkina T, Lee JY, Zhang S, Sorkin A, Bahar I. Neuropharmacology 161 107676 (2019)
  5. The Structure and Mechanism of Drug Transporters. Roberts AG. Methods Mol Biol 2342 193-234 (2021)
  6. Understanding the Contribution of Individual Amino Acid Residues in the Binding of Psychoactive Substances to Monoamine Transporters. Senior T, Botha MJ, Kennedy AR, Calvo-Castro J. ACS Omega 5 17223-17231 (2020)


Reviews citing this publication (70)

  1. Molecular Dynamics Simulation for All. Hollingsworth SA, Dror RO. Neuron 99 1129-1143 (2018)
  2. Emerging Diversity in Lipid-Protein Interactions. Corradi V, Sejdiu BI, Mesa-Galloso H, Abdizadeh H, Noskov SY, Marrink SJ, Tieleman DP. Chem Rev 119 5775-5848 (2019)
  3. A guide to plasma membrane solute carrier proteins. Pizzagalli MD, Bensimon A, Superti-Furga G. FEBS J 288 2784-2835 (2021)
  4. Role of Microbiota and Tryptophan Metabolites in the Remote Effect of Intestinal Inflammation on Brain and Depression. Waclawiková B, El Aidy S. Pharmaceuticals (Basel) 11 E63 (2018)
  5. Monoamine transporters: structure, intrinsic dynamics and allosteric regulation. Cheng MH, Bahar I. Nat Struct Mol Biol 26 545-556 (2019)
  6. Overview of Monoamine Transporters. Aggarwal S, Mortensen OV. Curr Protoc Pharmacol 79 12.16.1-12.16.17 (2017)
  7. Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. Gyimesi G, Pujol-Giménez J, Kanai Y, Hediger MA. Pflugers Arch 472 1177-1206 (2020)
  8. Insights into the mechanism and pharmacology of neurotransmitter sodium symporters. Navratna V, Gouaux E. Curr Opin Struct Biol 54 161-170 (2019)
  9. Serotonin transport in the 21st century. Rudnick G, Sandtner W. J Gen Physiol 151 1248-1264 (2019)
  10. Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy. Niello M, Gradisch R, Loland CJ, Stockner T, Sitte HH. Trends Pharmacol Sci 41 446-463 (2020)
  11. Potentiating SLC transporter activity: Emerging drug discovery opportunities. Rives ML, Javitch JA, Wickenden AD. Biochem Pharmacol 135 1-11 (2017)
  12. The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: Hereditary folate malabsorption. Zhao R, Aluri S, Goldman ID. Mol Aspects Med 53 57-72 (2017)
  13. A Perspective: Active Role of Lipids in Neurotransmitter Dynamics. Postila PA, Róg T. Mol Neurobiol 57 910-925 (2020)
  14. Molecular Mechanism of Nramp-Family Transition Metal Transport. Bozzi AT, Gaudet R. J Mol Biol 433 166991 (2021)
  15. Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective. Schlessinger A, Welch MA, van Vlijmen H, Korzekwa K, Swaan PW, Matsson P. Clin Pharmacol Ther 104 818-835 (2018)
  16. Neurobiology of Anorexia Nervosa: Serotonin Dysfunctions Link Self-Starvation with Body Image Disturbances through an Impaired Body Memory. Riva G. Front Hum Neurosci 10 600 (2016)
  17. Transporter oligomerization: form and function. Alguel Y, Cameron AD, Diallinas G, Byrne B. Biochem Soc Trans 44 1737-1744 (2016)
  18. Highlighting membrane protein structure and function: A celebration of the Protein Data Bank. Li F, Egea PF, Vecchio AJ, Asial I, Gupta M, Paulino J, Bajaj R, Dickinson MS, Ferguson-Miller S, Monk BC, Stroud RM. J Biol Chem 296 100557 (2021)
  19. Structural, Functional, and Molecular Imaging of Autism Spectrum Disorder. Li X, Zhang K, He X, Zhou J, Jin C, Shen L, Gao Y, Tian M, Zhang H. Neurosci Bull 37 1051-1071 (2021)
  20. SLC6 transporter oligomerization. Jayaraman K, Das AK, Luethi D, Szöllősi D, Schütz GJ, Reith MEA, Sitte HH, Stockner T. J Neurochem 157 919-929 (2021)
  21. Structure and Gating Dynamics of Na+/Cl- Coupled Neurotransmitter Transporters. Joseph D, Pidathala S, Mallela AK, Penmatsa A. Front Mol Biosci 6 80 (2019)
  22. Tales of tails in transporters. Mikros E, Diallinas G. Open Biol 9 190083 (2019)
  23. Amino Acid Transporter SLC6A14 (ATB0,+) - A Target in Combined Anti-cancer Therapy. Nałęcz KA. Front Cell Dev Biol 8 594464 (2020)
  24. Application of a Combined Approach to Identify New Psychoactive Street Drugs and Decipher Their Mechanisms at Monoamine Transporters. Mayer FP, Luf A, Nagy C, Holy M, Schmid R, Freissmuth M, Sitte HH. Curr Top Behav Neurosci 32 333-350 (2017)
  25. Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology. Fairweather SJ, Shah N, Brӧer S. Adv Exp Med Biol 21 13-127 (2021)
  26. A glimpse into the molecular mechanism of integral membrane proteins through hydrogen-deuterium exchange mass spectrometry. Martens C, Politis A. Protein Sci 29 1285-1301 (2020)
  27. May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Fava GA. Ther Adv Psychopharmacol 10 2045125320970325 (2020)
  28. Applications of Molecular Dynamics Simulation in Protein Study. Sinha S, Tam B, Wang SM. Membranes (Basel) 12 844 (2022)
  29. Toward a Molecular Basis of Cellular Nucleoside Transport in Humans. Wright NJ, Lee SY. Chem Rev 121 5336-5358 (2021)
  30. The Use of Multiscale Molecular Simulations in Understanding a Relationship between the Structure and Function of Biological Systems of the Brain: The Application to Monoamine Oxidase Enzymes. Vianello R, Domene C, Mavri J. Front Neurosci 10 327 (2016)
  31. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Sarparast A, Thomas K, Malcolm B, Stauffer CS. Psychopharmacology (Berl) 239 1945-1976 (2022)
  32. Analysis and measurement of serotonin. Szeitz A, Bandiera SM. Biomed Chromatogr 32 (2018)
  33. Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies. Wang X, Wang Y, Li X, Yu Z, Song C, Du Y. RSC Med Chem 12 1650-1671 (2021)
  34. Selective Serotonin Reuptake Inhibitor Use and Risk of Gastrointestinal and Intracranial Bleeding. Yuet WC, Derasari D, Sivoravong J, Mason D, Jann M. J Am Osteopath Assoc 119 102-111 (2019)
  35. Paroxetine-Overview of the Molecular Mechanisms of Action. Kowalska M, Nowaczyk J, Fijałkowski Ł, Nowaczyk A. Int J Mol Sci 22 1662 (2021)
  36. Transporter oligomerisation: roles in structure and function. Cecchetti C, Pyle E, Byrne B. Biochem Soc Trans 47 433-440 (2019)
  37. Insights into the Role of Membrane Lipids in the Structure, Function and Regulation of Integral Membrane Proteins. Renard K, Byrne B. Int J Mol Sci 22 9026 (2021)
  38. Targeting SLC transporters: small molecules as modulators and therapeutic opportunities. Schlessinger A, Zatorski N, Hutchinson K, Colas C. Trends Biochem Sci 48 801-814 (2023)
  39. An unfolding story: Small molecules remedy misfolded monoamine transporters. Kasture A, Stockner T, Freissmuth M, Sucic S. Int J Biochem Cell Biol 92 1-5 (2017)
  40. Chansporter complexes in cell signaling. Abbott GW. FEBS Lett 591 2556-2576 (2017)
  41. Genetics of methamphetamine use disorder: A systematic review and meta-analyses of gene association studies. Guerin AA, Nestler EJ, Berk M, Lawrence AJ, Rossell SL, Kim JH. Neurosci Biobehav Rev 120 48-74 (2021)
  42. Impact of disruption of secondary binding site S2 on dopamine transporter function. Zhen J, Reith ME. J Neurochem 138 694-699 (2016)
  43. Serotonin Syndrome/Serotonin Toxicity. Talton CW. Fed Pract 37 452-459 (2020)
  44. Novel Molecular Targets of Antidepressants. Jarończyk M, Walory J. Molecules 27 533 (2022)
  45. The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors. Reyes-Parada M, Iturriaga-Vasquez P. Expert Opin Drug Discov 11 969-981 (2016)
  46. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, Tirelli E, Pucci M, Ribaudo G, Oselladore E, Premoli M, Gianoncelli A, Uberti DL, Memo M. Int J Mol Sci 24 1329 (2023)
  47. The evolving biology of the proton-coupled folate transporter: New insights into regulation, structure, and mechanism. Hou Z, Gangjee A, Matherly LH. FASEB J 36 e22164 (2022)
  48. Discovery and Development of Monoamine Transporter Ligands. Aggarwal S, Mortensen OV. Adv Neurobiol 30 101-129 (2023)
  49. How Cryo-EM Has Expanded Our Understanding of Membrane Transporters. Baril SA, Gose T, Schuetz JD. Drug Metab Dispos 51 904-922 (2023)
  50. Ins and Outs of Rocker Switch Mechanism in Major Facilitator Superfamily of Transporters. Sauve S, Williamson J, Polasa A, Moradi M. Membranes (Basel) 13 462 (2023)
  51. Toward a Systematic Structural and Functional Annotation of Solute Carriers Transporters-Example of the SLC6 and SLC7 Families. Colas C. Front Pharmacol 11 1229 (2020)
  52. A comparative review on the well-studied GAT1 and the understudied BGT-1 in the brain. Bhatt M, Gauthier-Manuel L, Lazzarin E, Zerlotti R, Ziegler C, Bazzone A, Stockner T, Bossi E. Front Physiol 14 1145973 (2023)
  53. Advances in extraction methods, chemical constituents, pharmacological activities, molecular targets and toxicology of volatile oil from Acorus calamus var. angustatus Besser. Bai D, Li X, Wang S, Zhang T, Wei Y, Wang Q, Dong W, Song J, Gao P, Li Y, Wang S, Dai L. Front Pharmacol 13 1004529 (2022)
  54. Allosterically Linked Binding Sites in Serotonin Transporter Revealed by Single Molecule Force Spectroscopy. Zhu R, Sandtner W, Ahiable JEA, Newman AH, Freissmuth M, Sitte HH, Hinterdorfer P. Front Mol Biosci 7 99 (2020)
  55. Molecular basis and mechanism of action of Albizia julibrissin in depression treatment and clinical application of its formulae. Huang B, Wu Y, Li C, Tang Q, Zhang Y. Chin Herb Med 15 201-213 (2023)
  56. Serotonin Signaling through Lipid Membranes. Kalinichenko LS, Kornhuber J, Sinning S, Haase J, Müller CP. ACS Chem Neurosci 15 1298-1320 (2024)
  57. Taurine and Creatine Transporters as Potential Drug Targets in Cancer Therapy. Stary D, Bajda M. Int J Mol Sci 24 3788 (2023)
  58. A current view of serotonin transporters. De Felice LJ. F1000Res 5 F1000 Faculty Rev-1884 (2016)
  59. Advanced computational approaches to understand protein aggregation. Ghosh D, Biswas A, Radhakrishna M. Biophys Rev (Melville) 5 021302 (2024)
  60. Molecular mechanisms of action of stimulant novel psychoactive substances that target the high-affinity transporter for dopamine. Sahai MA, Opacka-Juffry J. Neuronal Signal 5 NS20210006 (2021)
  61. Elucidating the Mechanism Behind Sodium-Coupled Neurotransmitter Transporters by Reconstitution. Schmidt SG, Gether U, Loland CJ. Neurochem Res 47 127-137 (2022)
  62. Glycine Transporter 2: Mechanism and Allosteric Modulation. Frangos ZJ, Cantwell Chater RP, Vandenberg RJ. Front Mol Biosci 8 734427 (2021)
  63. Immunomodulatory Action of Substituted 1,3,4-Thiadiazines on the Course of Myocardial Infarction. Sarapultsev AP, Vassiliev PM, Sarapultsev PA, Chupakhin ON, Ianalieva LR, Sidorova LP. Molecules 23 E1611 (2018)
  64. Reconstitution of GABA, Glycine and Glutamate Transporters. Danbolt NC, López-Corcuera B, Zhou Y. Neurochem Res 47 85-110 (2022)
  65. Serotonin Transporter Ala276 Mouse: Novel Model to Assess the Neurochemical and Behavioral Impact of Thr276 Phosphorylation In Vivo. Meinke C, Quinlan MA, Paffenroth KC, Harrison FE, Fenollar-Ferrer C, Katamish RM, Stillman I, Ramamoorthy S, Blakely RD. Neurochem Res 47 37-60 (2022)
  66. The Serotonergic System and Bone Metabolism During Pregnancy and Lactation and the Implications of SSRI Use on the Maternal-Offspring Dyad. Fricke HP, Hernandez LL. J Mammary Gland Biol Neoplasia 28 7 (2023)
  67. Homology Modeling of Transporter Proteins. Sylte I, Gabrielsen M, Kristiansen K. Methods Mol Biol 2627 247-264 (2023)
  68. Ligand- and Structure-based Approaches for Transmembrane Transporter Modeling. Grandits M, Ecker GF. Curr Drug Res Rev 16 81-93 (2024)
  69. Oligomerization of Monoamine Transporters. Paul A, Shukla D. Subcell Biochem 104 119-137 (2024)
  70. Unlocking Therapeutic Synergy: Tailoring Drugs for Comorbidities such as Depression and Diabetes through Identical Molecular Targets in Different Cell Types. Coppola T, Daziano G, Legroux I, Béraud-Dufour S, Blondeau N, Lebrun P. Cells 12 2768 (2023)

Articles citing this publication (264)

  1. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Science 367 1444-1448 (2020)
  2. The role of interfacial lipids in stabilizing membrane protein oligomers. Gupta K, Donlan JAC, Hopper JTS, Uzdavinys P, Landreh M, Struwe WB, Drew D, Baldwin AJ, Stansfeld PJ, Robinson CV. Nature 541 421-424 (2017)
  3. Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut. Fung TC, Vuong HE, Luna CDG, Pronovost GN, Aleksandrova AA, Riley NG, Vavilina A, McGinn J, Rendon T, Forrest LR, Hsiao EY. Nat Microbiol 4 2064-2073 (2019)
  4. RCSB Protein Data Bank: Enabling biomedical research and drug discovery. Goodsell DS, Zardecki C, Di Costanzo L, Duarte JM, Hudson BP, Persikova I, Segura J, Shao C, Voigt M, Westbrook JD, Young JY, Burley SK. Protein Sci 29 52-65 (2020)
  5. Sampling alternative conformational states of transporters and receptors with AlphaFold2. Del Alamo D, Sala D, Mchaourab HS, Meiler J. Elife 11 e75751 (2022)
  6. Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport. Coleman JA, Yang D, Zhao Z, Wen PC, Yoshioka C, Tajkhorshid E, Gouaux E. Nature 569 141-145 (2019)
  7. Architecture and subunit arrangement of native AMPA receptors elucidated by cryo-EM. Zhao Y, Chen S, Swensen AC, Qian WJ, Gouaux E. Science 364 355-362 (2019)
  8. Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation. Lü W, Du J, Goehring A, Gouaux E. Science 355 eaal3729 (2017)
  9. Structural basis for recognition of diverse antidepressants by the human serotonin transporter. Coleman JA, Gouaux E. Nat Struct Mol Biol 25 170-175 (2018)
  10. Structural biology of solute carrier (SLC) membrane transport proteins. Bai X, Moraes TF, Reithmeier RAF. Mol Membr Biol 34 1-32 (2017)
  11. Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder. Xue W, Wang P, Tu G, Yang F, Zheng G, Li X, Li X, Chen Y, Yao X, Zhu F. Phys Chem Chem Phys 20 6606-6616 (2018)
  12. A direct interaction of cholesterol with the dopamine transporter prevents its out-to-inward transition. Zeppelin T, Ladefoged LK, Sinning S, Periole X, Schiøtt B. PLoS Comput Biol 14 e1005907 (2018)
  13. Direct PIP2 binding mediates stable oligomer formation of the serotonin transporter. Anderluh A, Hofmaier T, Klotzsch E, Kudlacek O, Stockner T, Sitte HH, Schütz GJ. Nat Commun 8 14089 (2017)
  14. Illumination of serotonin transporter mechanism and role of the allosteric site. Yang D, Gouaux E. Sci Adv 7 eabl3857 (2021)
  15. Structural insights into the inhibition of glycine reuptake. Shahsavar A, Stohler P, Bourenkov G, Zimmermann I, Siegrist M, Guba W, Pinard E, Sinning S, Seeger MA, Schneider TR, Dawson RJP, Nissen P. Nature 591 677-681 (2021)
  16. Structures of human ENT1 in complex with adenosine reuptake inhibitors. Wright NJ, Lee SY. Nat Struct Mol Biol 26 599-606 (2019)
  17. Substrate-bound outward-open structure of a Na+-coupled sialic acid symporter reveals a new Na+ site. Wahlgren WY, Dunevall E, North RA, Paz A, Scalise M, Bisignano P, Bengtsson-Palme J, Goyal P, Goyal P, Claesson E, Caing-Carlsson R, Andersson R, Beis K, Nilsson UJ, Farewell A, Pochini L, Indiveri C, Grabe M, Dobson RCJ, Abramson J, Ramaswamy S, Friemann R. Nat Commun 9 1753 (2018)
  18. Structural and mechanistic basis of proton-coupled metal ion transport in the SLC11/NRAMP family. Ehrnstorfer IA, Manatschal C, Arnold FM, Laederach J, Dutzler R. Nat Commun 8 14033 (2017)
  19. A Markov State-based Quantitative Kinetic Model of Sodium Release from the Dopamine Transporter. Razavi AM, Khelashvili G, Weinstein H. Sci Rep 7 40076 (2017)
  20. Structural basis of GABA reuptake inhibition. Motiwala Z, Aduri NG, Shaye H, Han GW, Lam JH, Katritch V, Cherezov V, Gati C. Nature 606 820-826 (2022)
  21. An Improved Strategy for Fluorescent Tagging of Membrane Proteins for Overexpression and Purification in Mammalian Cells. Rana MS, Wang X, Banerjee A. Biochemistry 57 6741-6751 (2018)
  22. Chemical and structural investigation of the paroxetine-human serotonin transporter complex. Coleman JA, Navratna V, Antermite D, Yang D, Bull JA, Gouaux E. Elife 9 e56427 (2020)
  23. Cholesterol binding to a conserved site modulates the conformation, pharmacology, and transport kinetics of the human serotonin transporter. Laursen L, Severinsen K, Kristensen KB, Periole X, Overby M, Müller HK, Schiøtt B, Sinning S. J Biol Chem 293 3510-3523 (2018)
  24. Hippocampal AMPA receptor assemblies and mechanism of allosteric inhibition. Yu J, Rao P, Clark S, Mitra J, Ha T, Gouaux E. Nature 594 448-453 (2021)
  25. Chemical profiles, pharmacological properties, and in silico studies provide new insights on Cycas pectinata. Tareq AM, Farhad S, Neshar Uddin ABM, Hoque M, Nasrin MS, Uddin MMR, Hasan M, Sultana A, Munira MS, Lyzu C, Moazzem Hossen SM, Ali Reza ASM, Emran TB. Heliyon 6 e04061 (2020)
  26. Electrogenic Binding of Intracellular Cations Defines a Kinetic Decision Point in the Transport Cycle of the Human Serotonin Transporter. Hasenhuetl PS, Freissmuth M, Sandtner W. J Biol Chem 291 25864-25876 (2016)
  27. GC-MS Phytochemical Profiling, Pharmacological Properties, and In Silico Studies of Chukrasia velutina Leaves: A Novel Source for Bioactive Agents. Jahan I, Tona MR, Sharmin S, Sayeed MA, Tania FZ, Paul A, Chy MNU, Rakib A, Emran TB, Simal-Gandara J. Molecules 25 E3536 (2020)
  28. Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter. Niu Y, Liu R, Guan C, Zhang Y, Chen Z, Hoerer S, Nar H, Chen L. Nature 601 280-284 (2022)
  29. The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter. Plenge P, Yang D, Salomon K, Laursen L, Kalenderoglou IE, Newman AH, Newman AH, Gouaux E, Coleman JA, Loland CJ. Nat Commun 12 5063 (2021)
  30. Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Dickens D, Chiduza GN, Wright GS, Pirmohamed M, Antonyuk SV, Hasnain SS. Sci Rep 7 43580 (2017)
  31. Substrate-induced conformational dynamics of the dopamine transporter. Nielsen AK, Möller IR, Wang Y, Rasmussen SGF, Lindorff-Larsen K, Rand KD, Loland CJ. Nat Commun 10 2714 (2019)
  32. Identification of novel inhibitors of the amino acid transporter B0 AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes. Cheng Q, Shah N, Bröer A, Fairweather S, Jiang Y, Schmoll D, Corry B, Bröer S. Br J Pharmacol 174 468-482 (2017)
  33. HPLC-PDA-MS/MS profiling of secondary metabolites from Opuntia ficus-indica cladode, peel and fruit pulp extracts and their antioxidant, neuroprotective effect in rats with aluminum chloride induced neurotoxicity. El-Hawary SS, Sobeh M, Badr WK, Abdelfattah MAO, Ali ZY, El-Tantawy ME, Rabeh MA, Wink M. Saudi J Biol Sci 27 2829-2838 (2020)
  34. Substrate-modulated unwinding of transmembrane helices in the NSS transporter LeuT. Merkle PS, Gotfryd K, Cuendet MA, Leth-Espensen KZ, Gether U, Loland CJ, Rand KD. Sci Adv 4 eaar6179 (2018)
  35. A partially-open inward-facing intermediate conformation of LeuT is associated with Na+ release and substrate transport. Terry DS, Kolster RA, Quick M, LeVine MV, Khelashvili G, Zhou Z, Weinstein H, Javitch JA, Blanchard SC. Nat Commun 9 230 (2018)
  36. Conformational transitions of the sodium-dependent sugar transporter, vSGLT. Paz A, Claxton DP, Kumar JP, Kazmier K, Bisignano P, Sharma S, Nolte SA, Liwag TM, Nayak V, Wright EM, Grabe M, Mchaourab HS, Abramson J. Proc Natl Acad Sci U S A 115 E2742-E2751 (2018)
  37. Structural basis of norepinephrine recognition and transport inhibition in neurotransmitter transporters. Pidathala S, Mallela AK, Joseph D, Penmatsa A. Nat Commun 12 2199 (2021)
  38. Transition metal ion FRET uncovers K+ regulation of a neurotransmitter/sodium symporter. Billesbølle CB, Mortensen JS, Sohail A, Schmidt SG, Shi L, Sitte HH, Gether U, Loland CJ. Nat Commun 7 12755 (2016)
  39. X-ray structure of LeuT in an inward-facing occluded conformation reveals mechanism of substrate release. Gotfryd K, Boesen T, Mortensen JS, Khelashvili G, Quick M, Terry DS, Missel JW, LeVine MV, Gourdon P, Blanchard SC, Javitch JA, Weinstein H, Loland CJ, Nissen P, Gether U. Nat Commun 11 1005 (2020)
  40. The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter. Plenge P, Abramyan AM, Sørensen G, Mørk A, Weikop P, Gether U, Bang-Andersen B, Shi L, Loland CJ. Nat Commun 11 1491 (2020)
  41. Amino Acid Transporters as Disease Modifiers and Drug Targets. Bröer S. SLAS Discov 23 303-320 (2018)
  42. Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Eshleman AJ, Nagarajan S, Wolfrum KM, Reed JF, Swanson TL, Nilsen A, Janowsky A. Psychopharmacology (Berl) 236 939-952 (2019)
  43. Antidepressant, anxiolytic, antipyretic, and thrombolytic profiling of methanol extract of the aerial part of Piper nigrum: In vivo, in vitro, and in silico approaches. Emon NU, Alam S, Rudra S, Riya SR, Paul A, Hossen SMM, Kulsum U, Ganguly A. Food Sci Nutr 9 833-846 (2021)
  44. Dimer Interface of the Human Serotonin Transporter and Effect of the Membrane Composition. Periole X, Zeppelin T, Schiøtt B. Sci Rep 8 5080 (2018)
  45. Therapeutic Potentials of Syzygium fruticosum Fruit (Seed) Reflected into an Array of Pharmacological Assays and Prospective Receptors-Mediated Pathways. Moni JNR, Adnan M, Tareq AM, Kabir MI, Reza ASMA, Nasrin MS, Chowdhury KH, Sayem SAJ, Rahman MA, Alam AK, Alam SB, Sakib MA, Oh KK, Cho DH, Capasso R. Life (Basel) 11 155 (2021)
  46. Allosteric modulation of human dopamine transporter activity under conditions promoting its dimerization. Cheng MH, Garcia-Olivares J, Wasserman S, DiPietro J, Bahar I. J Biol Chem 292 12471-12482 (2017)
  47. Structural basis of pH-dependent client binding by ERp44, a key regulator of protein secretion at the ER-Golgi interface. Watanabe S, Harayama M, Kanemura S, Sitia R, Inaba K. Proc Natl Acad Sci U S A 114 E3224-E3232 (2017)
  48. Identification of an allosteric binding site on the human glycine transporter, GlyT2, for bioactive lipid analgesics. Mostyn SN, Wilson KA, Schumann-Gillett A, Frangos ZJ, Shimmon S, Rawling T, Ryan RM, O'Mara ML, Vandenberg RJ. Elife 8 e47150 (2019)
  49. Structural elements required for coupling ion and substrate transport in the neurotransmitter transporter homolog LeuT. Zhang YW, Tavoulari S, Sinning S, Aleksandrova AA, Forrest LR, Rudnick G. Proc Natl Acad Sci U S A 115 E8854-E8862 (2018)
  50. Intervention in Neuropsychiatric Disorders by Suppressing Inflammatory and Oxidative Stress Signal and Exploration of In Silico Studies for Potential Lead Compounds from Holigarna caustica (Dennst.) Oken leaves. Adnan M, Chy MNU, Kamal ATMM, Chowdhury KAA, Rahman MA, Reza ASMA, Moniruzzaman M, Rony SR, Nasrin MS, Azad MOK, Park CH, Lim YS, Cho DH. Biomolecules 10 E561 (2020)
  51. Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder. Zheng G, Xue W, Yang F, Zhang Y, Chen Y, Yao X, Zhu F. Phys Chem Chem Phys 19 28885-28896 (2017)
  52. ATP modulates SLC7A5 (LAT1) synergistically with cholesterol. Cosco J, Scalise M, Colas C, Galluccio M, Martini R, Rovella F, Mazza T, Ecker GF, Indiveri C. Sci Rep 10 16738 (2020)
  53. Dopamine transporter oligomerization involves the scaffold domain, but spares the bundle domain. Jayaraman K, Morley AN, Szöllősi D, Wassenaar TA, Sitte HH, Stockner T. PLoS Comput Biol 14 e1006229 (2018)
  54. Identification of a Novel Allosteric Modulator of the Human Dopamine Transporter. Aggarwal S, Liu X, Rice C, Menell P, Clark PJ, Paparoidamis N, Xiao YC, Salvino JM, Fontana ACK, España RA, Kortagere S, Mortensen OV. ACS Chem Neurosci 10 3718-3730 (2019)
  55. Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders. Zou MF, Cao J, Abramyan AM, Kopajtic T, Zanettini C, Guthrie DA, Rais R, Slusher BS, Shi L, Loland CJ, Newman AH. J Med Chem 60 10172-10187 (2017)
  56. Structure-based discovery of conformationally selective inhibitors of the serotonin transporter. Singh I, Seth A, Billesbølle CB, Braz J, Rodriguiz RM, Roy K, Bekele B, Craik V, Huang XP, Boytsov D, Pogorelov VM, Lak P, O'Donnell H, Sandtner W, Irwin JJ, Roth BL, Basbaum AI, Wetsel WC, Manglik A, Shoichet BK, Rudnick G. Cell 186 2160-2175.e17 (2023)
  57. The allosteric mechanism of substrate-specific transport in SLC6 is mediated by a volumetric sensor. LeVine MV, Terry DS, Khelashvili G, Siegel ZS, Quick M, Javitch JA, Blanchard SC, Weinstein H. Proc Natl Acad Sci U S A 116 15947-15956 (2019)
  58. Characterization of transgenic mouse lines for labeling type I and type II afferent neurons in the cochlea. Vyas P, Wu JS, Jimenez A, Glowatzki E, Fuchs PA. Sci Rep 9 5549 (2019)
  59. Dopamine Transporter Amino and Carboxyl Termini Synergistically Contribute to Substrate and Inhibitor Affinities. Sweeney CG, Tremblay BP, Stockner T, Sitte HH, Melikian HE. J Biol Chem 292 1302-1309 (2017)
  60. Handling of intracellular K+ determines voltage dependence of plasmalemmal monoamine transporter function. Bhat S, Niello M, Schicker K, Pifl C, Sitte HH, Freissmuth M, Sandtner W. Elife 10 e67996 (2021)
  61. Structural insights into the mechanism of the sodium/iodide symporter. Ravera S, Nicola JP, Salazar-De Simone G, Sigworth FJ, Karakas E, Amzel LM, Bianchet MA, Carrasco N. Nature 612 795-801 (2022)
  62. The role of transmembrane segment 5 (TM5) in Na2 release and the conformational transition of neurotransmitter:sodium symporters toward the inward-open state. Stolzenberg S, Li Z, Quick M, Malinauskaite L, Nissen P, Weinstein H, Javitch JA, Shi L. J Biol Chem 292 7372-7384 (2017)
  63. A non-helical region in transmembrane helix 6 of hydrophobic amino acid transporter MhsT mediates substrate recognition. Focht D, Neumann C, Lyons J, Eguskiza Bilbao A, Blunck R, Malinauskaite L, Schwarz IO, Javitch JA, Quick M, Nissen P. EMBO J 40 e105164 (2021)
  64. Chemical Profiles and Pharmacological Properties with in Silico Studies on Elatostema papillosum Wedd. Uddin MZ, Paul A, Rakib A, Sami SA, Mahmud S, Rana MS, Hossain S, Tareq AM, Dutta M, Emran TB, Simal-Gandara J. Molecules 26 809 (2021)
  65. Kinetic Models of Secondary Active Transporters. Burtscher V, Schicker K, Freissmuth M, Sandtner W. Int J Mol Sci 20 E5365 (2019)
  66. The LeuT-fold neurotransmitter:sodium symporter MhsT has two substrate sites. Quick M, Abramyan AM, Wiriyasermkul P, Weinstein H, Shi L, Javitch JA. Proc Natl Acad Sci U S A 115 E7924-E7931 (2018)
  67. Thermostabilization and purification of the human dopamine transporter (hDAT) in an inhibitor and allosteric ligand bound conformation. Navratna V, Tosh DK, Jacobson KA, Gouaux E. PLoS One 13 e0200085 (2018)
  68. Chloride-dependent conformational changes in the GlyT1 glycine transporter. Zhang YW, Uchendu S, Leone V, Bradshaw RT, Sangwa N, Forrest LR, Rudnick G. Proc Natl Acad Sci U S A 118 e2017431118 (2021)
  69. Detergent-free purification and reconstitution of functional human serotonin transporter (SERT) using diisobutylene maleic acid (DIBMA) copolymer. Dilworth MV, Findlay HE, Booth PJ. Biochim Biophys Acta Biomembr 1863 183602 (2021)
  70. Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. Tosh DK, Janowsky A, Eshleman AJ, Warnick E, Gao ZG, Chen Z, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA. J Med Chem 60 3109-3123 (2017)
  71. Targeting of dopamine transporter to filopodia requires an outward-facing conformation of the transporter. Ma S, Cheng MH, Guthrie DA, Newman AH, Newman AH, Bahar I, Sorkin A. Sci Rep 7 5399 (2017)
  72. A structural model of the human serotonin transporter in an outward-occluded state. Hellsberg E, Ecker GF, Stary-Weinzinger A, Forrest LR. PLoS One 14 e0217377 (2019)
  73. Computation-guided analysis of paroxetine binding to hSERT reveals functionally important structural elements and dynamics. Abramyan AM, Slack RD, Meena S, Davis BA, Newman AH, Singh SK, Shi L. Neuropharmacology 161 107411 (2019)
  74. Consensus designs and thermal stability determinants of a human glutamate transporter. Cirri E, Brier S, Assal R, Canul-Tec JC, Chamot-Rooke J, Reyes N. Elife 7 e40110 (2018)
  75. Deeper Insights on Cnesmone javanica Blume Leaves Extract: Chemical Profiles, Biological Attributes, Network Pharmacology and Molecular Docking. Obaidullah AJ, Alanazi MM, Alsaif NA, Mahdi WA, Fantoukh OI, Tareq AM, Sami SA, Alqahtani AM, Emran TB. Plants (Basel) 10 728 (2021)
  76. Environmental enrichment reduces innate anxiety with no effect on depression-like behaviour in mice lacking the serotonin transporter. Rogers J, Li S, Lanfumey L, Hannan AJ, Renoir T. Behav Brain Res 332 355-361 (2017)
  77. Integrated AlphaFold2 and DEER investigation of the conformational dynamics of a pH-dependent APC antiporter. Del Alamo D, DeSousa L, Nair RM, Rahman S, Meiler J, Mchaourab HS. Proc Natl Acad Sci U S A 119 e2206129119 (2022)
  78. Novel Chemical Scaffolds to Inhibit the Neutral Amino Acid Transporter B0AT1 (SLC6A19), a Potential Target to Treat Metabolic Diseases. Yadav A, Shah N, Tiwari PK, Javed K, Cheng Q, Aidhen IS, Bröer S. Front Pharmacol 11 140 (2020)
  79. Structure of the human cation-chloride cotransport KCC1 in an outward-open state. Zhao Y, Shen J, Wang Q, Ruiz Munevar MJ, Vidossich P, De Vivo M, Zhou M, Cao E. Proc Natl Acad Sci U S A 119 e2109083119 (2022)
  80. Antioxidant-Rich Woodfordia fruticosa Leaf Extract Alleviates Depressive-Like Behaviors and Impede Hyperglycemia. Tayab MA, Chowdhury KAA, Jabed M, Mohammed Tareq S, Kamal ATMM, Islam MN, Uddin AMK, Hossain MA, Emran TB, Simal-Gandara J. Plants (Basel) 10 287 (2021)
  81. Chronic Intake of the Selective Serotonin Reuptake Inhibitor Fluoxetine Enhances Atherosclerosis. Rami M, Guillamat-Prats R, Rinne P, Salvermoser M, Ring L, Bianchini M, Blanchet X, Megens RTA, Döring Y, Walzog B, Soehnlein O, Weber C, Faussner A, Steffens S. Arterioscler Thromb Vasc Biol 38 1007-1019 (2018)
  82. Computational characterization of the selective inhibition of human norepinephrine and serotonin transporters by an escitalopram scaffold. Zheng G, Yang F, Fu T, Tu G, Chen Y, Yao X, Xue W, Zhu F. Phys Chem Chem Phys 20 29513-29527 (2018)
  83. Cryo-EM structure of the human NKCC1 transporter reveals mechanisms of ion coupling and specificity. Neumann C, Rosenbaek LL, Flygaard RK, Habeck M, Karlsen JL, Wang Y, Lindorff-Larsen K, Gad HH, Hartmann R, Lyons JA, Fenton RA, Nissen P. EMBO J 41 e110169 (2022)
  84. High-resolution structures with bound Mn<sup>2+</sup> and Cd<sup>2+</sup> map the metal import pathway in an Nramp transporter. Ray S, Berry SP, Wilson EA, Zhang CH, Shekhar M, Singharoy A, Gaudet R. Elife 12 e84006 (2023)
  85. Phosphatidylinositol 4,5-bisphosphate (PIP2) facilitates norepinephrine transporter dimerization and modulates substrate efflux. Luethi D, Maier J, Rudin D, Szöllősi D, Angenoorth TJF, Stankovic S, Schittmayer M, Burger I, Yang JW, Jaentsch K, Holy M, Das AK, Brameshuber M, Camacho-Hernandez GA, Casiraghi A, Newman AH, Kudlacek O, Birner-Gruenberger R, Stockner T, Schütz GJ, Sitte HH. Commun Biol 5 1259 (2022)
  86. Resculpting the binding pocket of APC superfamily LeuT-fold amino acid transporters. Edwards N, Anderson CMH, Conlon NJ, Watson AK, Hall RJ, Cheek TR, Embley TM, Thwaites DT. Cell Mol Life Sci 75 921-938 (2018)
  87. Shared dynamics of LeuT superfamily members and allosteric differentiation by structural irregularities and multimerization. Ponzoni L, Zhang S, Cheng MH, Bahar I. Philos Trans R Soc Lond B Biol Sci 373 20170177 (2018)
  88. The N Terminus Specifies the Switch between Transport Modes of the Human Serotonin Transporter. Kern C, Erdem FA, El-Kasaby A, Sandtner W, Freissmuth M, Sucic S. J Biol Chem 292 3603-3613 (2017)
  89. A label-free approach to detect ligand binding to cell surface proteins in real time. Burtscher V, Hotka M, Li Y, Freissmuth M, Sandtner W. Elife 7 e34944 (2018)
  90. Combined in vitro and in silico approaches to the assessment of stimulant properties of novel psychoactive substances - The case of the benzofuran 5-MAPB. Sahai MA, Davidson C, Khelashvili G, Barrese V, Dutta N, Weinstein H, Opacka-Juffry J. Prog Neuropsychopharmacol Biol Psychiatry 75 1-9 (2017)
  91. Studies of structural determinants of substrate binding in the Creatine Transporter (CreaT, SLC6A8) using molecular models. Colas C, Banci G, Martini R, Ecker GF. Sci Rep 10 6241 (2020)
  92. The allosteric citalopram binding site differentially interferes with neuronal firing rate and SERT trafficking in serotonergic neurons. Matthäus F, Haddjeri N, Sánchez C, Martí Y, Bahri S, Rovera R, Schloss P, Lau T. Eur Neuropsychopharmacol 26 1806-1817 (2016)
  93. Unravelling the Biological Activities of the Byttneria pilosa Leaves Using Experimental and Computational Approaches. Jyoti MA, Barua N, Hossain MS, Hoque M, Bristy TA, Mahmud S, Kamruzzaman, Adnan M, Chy MNU, Chy MNU, Paul A, Hossain ME, Emran TB, Simal-Gandara J. Molecules 25 E4737 (2020)
  94. Unveiling Pharmacological Responses and Potential Targets Insights of Identified Bioactive Constituents of Cuscuta reflexa Roxb. Leaves through In Vivo and In Silico Approaches. Adnan M, Chy MNU, Kamal ATMM, Chowdhury MR, Islam MS, Hossain MA, Tareq AM, Bhuiyan MIH, Uddin MN, Tahamina A, Azad MOK, Lim YS, Cho DH. Pharmaceuticals (Basel) 13 E50 (2020)
  95. Interaction of Cholesterol With the Human SLC1A5 (ASCT2): Insights Into Structure/Function Relationships. Scalise M, Pochini L, Cosco J, Aloe E, Mazza T, Console L, Esposito A, Indiveri C. Front Mol Biosci 6 110 (2019)
  96. Sequence determinants of the Caenhorhabditis elegans dopamine transporter dictating in vivo axonal export and synaptic localization. Robinson SB, Hardaway JA, Hardie SL, Wright J, Glynn RM, Bermingham DP, Han Q, Sturgeon SM, Freeman P, Blakely RD. Mol Cell Neurosci 78 41-51 (2017)
  97. The substrate import mechanism of the human serotonin transporter. Chan MC, Selvam B, Young HJ, Procko E, Shukla D. Biophys J 121 715-730 (2022)
  98. An Extra Amino Acid Residue in Transmembrane Domain 10 of the γ-Aminobutyric Acid (GABA) Transporter GAT-1 Is Required for Efficient Ion-coupled Transport. Dayan O, Nagarajan A, Shah R, Ben-Yona A, Forrest LR, Kanner BI. J Biol Chem 292 5418-5428 (2017)
  99. Competition between Li+ and Na+ in sodium transporters and receptors: Which Na+-Binding sites are "therapeutic" Li+ targets? Dudev T, Mazmanian K, Lim C. Chem Sci 9 4093-4103 (2018)
  100. Direct assessment of substrate binding to the Neurotransmitter:Sodium Symporter LeuT by solid state NMR. Erlendsson S, Gotfryd K, Larsen FH, Mortensen JS, Geiger MA, van Rossum BJ, Oschkinat H, Gether U, Teilum K, Loland CJ. Elife 6 e19314 (2017)
  101. Function and Regulation of Acid Resistance Antiporters. Krammer EM, Prévost M. J Membr Biol 252 465-481 (2019)
  102. Locking Two Rigid-body Bundles in an Outward-Facing Conformation: The Ion-coupling Mechanism in a LeuT-fold Transporter. Li J, Zhao Z, Tajkhorshid E. Sci Rep 9 19479 (2019)
  103. New insights on the phytochemical intervention for the treatment of neuropsychiatric disorders using the leaves of Michelia champaca: an in vivo and in silico approach. V H P, M K J, H R R, Shivamurthy VKN, Patil SM, Shirahatti PS, Ramu R. Pharm Biol 60 1656-1668 (2022)
  104. Relationships between Inhibition, Transport and Enhanced Transport via the Organic Cation Transporter 1. Jensen O, Gebauer L, Brockmöller J, Dücker C. Int J Mol Sci 23 2007 (2022)
  105. Structural insights into GABA transport inhibition using an engineered neurotransmitter transporter. Joseph D, Nayak SR, Penmatsa A. EMBO J 41 e110735 (2022)
  106. Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter. Fan M, Zhang J, Lee CL, Zhang J, Feng L. Nature 614 788-793 (2023)
  107. Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram. Coleman JA, Green EM, Gouaux E. J Vis Exp (2016)
  108. Fluorescence-detection size-exclusion chromatography utilizing nanobody technology for expression screening of membrane proteins. Jin F, Shen C, Wang Y, Wang M, Sun M, Hattori M. Commun Biol 4 366 (2021)
  109. From linked open data to molecular interaction: studying selectivity trends for ligands of the human serotonin and dopamine transporter. Zdrazil B, Hellsberg E, Viereck M, Ecker GF. Medchemcomm 7 1819-1831 (2016)
  110. Functional Characterization of the Dopaminergic Psychostimulant Sydnocarb as an Allosteric Modulator of the Human Dopamine Transporter. Aggarwal S, Cheng MH, Salvino JM, Bahar I, Mortensen OV. Biomedicines 9 634 (2021)
  111. Heterogeneities in Axonal Structure and Transporter Distribution Lower Dopamine Reuptake Efficiency. Kaya C, Cheng MH, Block ER, Bartol TM, Sejnowski TJ, Sorkin A, Faeder JR, Bahar I. eNeuro 5 ENEURO.0298-17.2017 (2018)
  112. Human Serotonin Transporter Coding Variation Establishes Conformational Bias with Functional Consequences. Quinlan MA, Krout D, Katamish RM, Robson MJ, Nettesheim C, Gresch PJ, Mash DC, Henry LK, Blakely RD. ACS Chem Neurosci 10 3249-3260 (2019)
  113. Identification of a New Allosteric Binding Site for Cocaine in Dopamine Transporter. Xu L, Chen LY. J Chem Inf Model 60 3958-3968 (2020)
  114. Investigating the Mechanism of Sodium Binding to SERT Using Direct Simulations. Szöllősi D, Stockner T. Front Cell Neurosci 15 673782 (2021)
  115. Modification of a Putative Third Sodium Site in the Glycine Transporter GlyT2 Influences the Chloride Dependence of Substrate Transport. Benito-Muñoz C, Perona A, Abia D, Dos Santos HG, Núñez E, Aragón C, López-Corcuera B. Front Mol Neurosci 11 347 (2018)
  116. Molecular basis for substrate recognition and transport of human GABA transporter GAT1. Zhu A, Huang J, Kong F, Tan J, Lei J, Yuan Y, Yan C. Nat Struct Mol Biol 30 1012-1022 (2023)
  117. Structural determinants of cholesterol recognition in helical integral membrane proteins. Marlow B, Kuenze G, Li B, Sanders CR, Meiler J. Biophys J 120 1592-1604 (2021)
  118. Allosteric Modulator KM822 Attenuates Behavioral Actions of Amphetamine in Caenorhabditis elegans through Interactions with the Dopamine Transporter DAT-1. Refai O, Aggarwal S, Cheng MH, Gichi Z, Salvino JM, Bahar I, Blakely RD, Mortensen OV. Mol Pharmacol 101 123-131 (2022)
  119. Extracellular loops of the serotonin transporter act as a selectivity filter for drug binding. Esendir E, Burtscher V, Coleman JA, Zhu R, Gouaux E, Freissmuth M, Sandtner W. J Biol Chem 297 100863 (2021)
  120. Focus on Human Monoamine Transporter Selectivity. New Human DAT and NET Models, Experimental Validation, and SERT Affinity Exploration. Ortore G, Orlandini E, Betti L, Giannaccini G, Mazzoni MR, Camodeca C, Nencetti S. ACS Chem Neurosci 11 3214-3232 (2020)
  121. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step. Chan SW, Shafi T, Ford RC. Viruses 13 2306 (2021)
  122. Occlusion of the human serotonin transporter is mediated by serotonin-induced conformational changes in the bundle domain. Gradisch R, Szöllősi D, Niello M, Lazzarin E, Sitte HH, Stockner T. J Biol Chem 298 101613 (2022)
  123. Persistent binding at dopamine transporters determines sustained psychostimulant effects. Niello M, Sideromenos S, Gradisch R, O Shea R, Schwazer J, Maier J, Kastner N, Sandtner W, Jäntsch K, Lupica CR, Hoffman AF, Lubec G, Loland CJ, Stockner T, Pollak DD, Baumann MH, Sitte HH. Proc Natl Acad Sci U S A 120 e2114204120 (2023)
  124. Structure Modeling of the Norepinephrine Transporter. Góral I, Łątka K, Bajda M. Biomolecules 10 E102 (2020)
  125. Structure-Function of the High Affinity Substrate Binding Site (S1) of Human Norepinephrine Transporter. Jha P, Ragnarsson L, Lewis RJ. Front Pharmacol 11 217 (2020)
  126. Tamoxifen Directly Interacts with the Dopamine Transporter. Mikelman SR, Guptaroy B, Schmitt KC, Jones KT, Zhen J, Reith MEA, Gnegy ME. J Pharmacol Exp Ther 367 119-128 (2018)
  127. The Influence of 5-HTTLPR, BDNF Rs6265 and COMT Rs4680 Polymorphisms on Impulsivity in Bipolar Disorder: The Role of Gender. Boscutti A, Pigoni A, Delvecchio G, Lazzaretti M, Mandolini GM, Girardi P, Ferro A, Sala M, Abbiati V, Cappucciati M, Bellani M, Perlini C, Rossetti MG, Balestrieri M, Damante G, Bonivento C, Rossi R, Finos L, Serretti A, Brambilla P, The Gecobip Group. Genes (Basel) 13 482 (2022)
  128. Two Lignan Glycosides from Albizia julibrissin Durazz. Noncompetitively Inhibit Serotonin Transporter. Huang B, Liu H, Wu Y, Li C, Tang Q, Zhang YW. Pharmaceuticals (Basel) 15 344 (2022)
  129. CNS anti-depressant, anxiolytic and analgesic effects of Ganoderma applanatum (mushroom) along with ligand-receptor binding screening provide new insights: Multi-disciplinary approaches. Hossen SMM, Islam MJ, Hossain MR, Barua A, Uddin MG, Emon NU. Biochem Biophys Rep 27 101062 (2021)
  130. Cryo-EM structure of GABA transporter 1 reveals substrate recognition and transport mechanism. Nayak SR, Joseph D, Höfner G, Dakua A, Athreya A, Wanner KT, Kanner BI, Penmatsa A. Nat Struct Mol Biol 30 1023-1032 (2023)
  131. Functional Reconstitution of Membrane Proteins Derived From Eukaryotic Cell-Free Systems. Dondapati SK, Lübberding H, Zemella A, Thoring L, Wüstenhagen DA, Kubick S. Front Pharmacol 10 917 (2019)
  132. Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder. Yoshimura R, Katsuki A, Atake K, Hori H, Igata R, Konishi Y. Neuropsychiatr Dis Treat 13 437-441 (2017)
  133. Multitarget Approach to Drug Candidates against Alzheimer's Disease Related to AChE, SERT, BACE1 and GSK3β Protein Targets. Ivanova L, Karelson M, Dobchev DA. Molecules 25 E1846 (2020)
  134. Structures and membrane interactions of native serotonin transporter in complexes with psychostimulants. Yang D, Zhao Z, Tajkhorshid E, Gouaux E. Proc Natl Acad Sci U S A 120 e2304602120 (2023)
  135. Substitutions that lock and unlock the proton-coupled folate transporter (PCFT-SLC46A1) in an inward-open conformation. Aluri S, Zhao R, Lin K, Shin DS, Fiser A, Goldman ID. J Biol Chem 294 7245-7258 (2019)
  136. 3D similarities between the binding sites of monoaminergic target proteins. Núñez-Vivanco G, Fierro A, Moya P, Iturriaga-Vásquez P, Reyes-Parada M. PLoS One 13 e0200637 (2018)
  137. A Photoswitchable Inhibitor of the Human Serotonin Transporter. Cheng B, Morstein J, Ladefoged LK, Maesen JB, Schiøtt B, Sinning S, Trauner D. ACS Chem Neurosci 11 1231-1237 (2020)
  138. Advancing insights on β-cyclodextrin inclusion complexes with SSRIs through lens of X-ray diffraction and DFT calculation. Aree T. Int J Pharm 609 121113 (2021)
  139. Computational Methods for the Identification of Molecular Targets of Toxic Food Additives. Butylated Hydroxytoluene as a Case Study. Tortosa V, Pietropaolo V, Brandi V, Macari G, Pasquadibisceglie A, Polticelli F. Molecules 25 E2229 (2020)
  140. Direct visualization of an antidepressant analog using surface-enhanced Raman scattering in the brain. Tanuma M, Kasai A, Bando K, Kotoku N, Harada K, Minoshima M, Higashino K, Kimishima A, Arai M, Ago Y, Seiriki K, Kikuchi K, Kawata S, Fujita K, Hashimoto H. JCI Insight 5 133348 (2020)
  141. Effect of palmitoylation on the dimer formation of the human dopamine transporter. Zeppelin T, Pedersen KB, Berglund NA, Periole X, Schiøtt B. Sci Rep 11 4164 (2021)
  142. Exploration of insights, opportunities and caveats provided by the X-ray structures of hSERT. Topiol S, Bang-Andersen B, Sanchez C, Bøgesø KP. Bioorg Med Chem Lett 26 5058-5064 (2016)
  143. Expression and purification of a functional heteromeric GABAA receptor for structural studies. Claxton DP, Gouaux E. PLoS One 13 e0201210 (2018)
  144. In Vitro Assays for the Functional Characterization of the Dopamine Transporter (DAT). Aggarwal S, Mortensen OV. Curr Protoc Pharmacol 79 12.17.1-12.17.21 (2017)
  145. Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS) and Their Discrimination by the Dopamine Transporter-In Silico and In Vitro Exploration of Dissociative Diarylethylamines. Sahai MA, Davidson C, Dutta N, Opacka-Juffry J. Brain Sci 8 E63 (2018)
  146. Photoswitchable ORG25543 Congener Enables Optical Control of Glycine Transporter 2. Mostyn SN, Sarker S, Muthuraman P, Raja A, Shimmon S, Rawling T, Cioffi CL, Vandenberg RJ. ACS Chem Neurosci 11 1250-1258 (2020)
  147. Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study. Kim E, Howes OD, Kim BH, Chon MW, Seo S, Turkheimer FE, Lee JS, Lee YS, Kwon JS. Clin Pharmacokinet 56 371-381 (2017)
  148. Sodium Binding Stabilizes the Outward-Open State of SERT by Limiting Bundle Domain Motions. Szöllősi D, Stockner T. Cells 11 255 (2022)
  149. Targeting Neuroblastoma Cell Surface Proteins: Recommendations for Homology Modeling of hNET, ALK, and TrkB. Haddad Y, Heger Z, Adam V. Front Mol Neurosci 10 7 (2017)
  150. The Impact of Software Used and the Type of Target Protein on Molecular Docking Accuracy. Ivanova L, Karelson M. Molecules 27 9041 (2022)
  151. Transporters through the looking glass. An insight into the mechanisms of ion-coupled transport and methods that help reveal them. Majumder P, Mallela AK, Penmatsa A. J Indian Inst Sci 98 283-300 (2018)
  152. Lasia spinosa (L.) thw. attenuates chemically induced behavioral disorders in experimental and computational models. Reza ASMA, Sakib MA, Nasrin MS, Khan J, Khan MF, Hossen MA, Ali MH, Haque MA. Heliyon 9 e16754 (2023)
  153. A Dynamic Interaction of Coomassie Dye with the Glycine Transporters N-termini. Juhasova A, Baliova M, Jursky F. Protein J 35 371-378 (2016)
  154. Anion-Based Self-assembly of Resorcin[4]arenes and Pyrogallol[4]arenes. Chwastek M, Cmoch P, Szumna A. J Am Chem Soc 144 5350-5358 (2022)
  155. Bile Acids Gate Dopamine Transporter Mediated Currents. Romanazzi T, Zanella D, Cheng MH, Smith B, Carter AM, Galli A, Bahar I, Bossi E. Front Chem 9 753990 (2021)
  156. Deciphering the CNS anti-depressant, antioxidant and cytotoxic profiling of methanol and aqueous extracts of Trametes versicolor and molecular interactions of its phenolic compounds. Moazzem Hossen SM, Akramul Hoque Tanim M, Shahadat Hossain M, Ahmed Sami S, Uddin Emon N. Saudi J Biol Sci 28 6375-6383 (2021)
  157. Determining Ligand and Ion-Induced Conformational Changes in Serotonin Transporter with Its Fluorescent Substrates. Li M, Chen Q, Zhang YW. Int J Mol Sci 23 10919 (2022)
  158. Identification of novel serotonin reuptake inhibitors targeting central and allosteric binding sites: A virtual screening and molecular dynamics simulations study. Erol I, Aksoydan B, Kantarcioglu I, Salmas RE, Durdagi S. J Mol Graph Model 74 193-202 (2017)
  159. Investigating the lipid fingerprint of SLC6 neurotransmitter transporters: a comparison of dDAT, hDAT, hSERT, and GlyT2. Wilson KA, Wang L, Lin YC, O'Mara ML. BBA Adv 1 100010 (2021)
  160. Mapping of Ion and Substrate Binding Sites in Human Sodium Iodide Symporter (hNIS). Zhekova HR, Sakuma T, Johnson R, Concilio SC, Lech PJ, Zdravkovic I, Damergi M, Suksanpaisan L, Peng KW, Russell SJ, Noskov S. J Chem Inf Model 60 1652-1665 (2020)
  161. Molecular dynamics of conformation-specific dopamine transporter-inhibitor complexes. Jean B, Surratt CK, Madura JD. J Mol Graph Model 76 143-151 (2017)
  162. Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells. Haddad Y, Charousova M, Zivotska H, Splichal Z, Merlos Rodrigo MA, Michalkova H, Krizkova S, Tesarova B, Richtera L, Vitek P, Stokowa-Soltys K, Hynek D, Milosavljevic V, Rex S, Heger Z. J Nanobiotechnology 18 95 (2020)
  163. On the Role of a Conserved Methionine in the Na+-Coupling Mechanism of a Neurotransmitter Transporter Homolog. Zhou W, Trinco G, Slotboom DJ, Forrest LR, Faraldo-Gómez JD. Neurochem Res 47 163-175 (2022)
  164. Proteochemometric Modeling Identifies Chemically Diverse Norepinephrine Transporter Inhibitors. Bongers BJ, Sijben HJ, Hartog PBR, Tarnovskiy A, IJzerman AP, Heitman LH, van Westen GJP. J Chem Inf Model 63 1745-1755 (2023)
  165. SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila. Dunham KE, Venton BJ. J Neurochem 162 404-416 (2022)
  166. Synthesis and Docking of Novel 3-Indolylpropyl Derivatives as New Polypharmacological Agents Displaying Affinity for 5-HT1A R/SERT. Pessoa-Mahana H, Silva-Matus P, Pessoa-Mahana CD, Chung H, Iturriaga-Vásquez P, Quiroz G, Möller-Acuña P, Zapata-Torres G, Saitz-Barría C, Araya-Maturana R, Reyes-Parada M. Arch Pharm (Weinheim) 350 (2017)
  167. A Novel Bromine-Containing Paroxetine Analogue Provides Mechanistic Clues for Binding Ambiguity at the Central Primary Binding Site of the Serotonin Transporter. Slack RD, Abramyan AM, Tang H, Meena S, Davis BA, Bonifazi A, Giancola JB, Deschamps JR, Naing S, Yano H, Singh SK, Newman AH, Shi L. ACS Chem Neurosci 10 3946-3952 (2019)
  168. Analysis of Binding Determinants for Different Classes of Competitive and Noncompetitive Inhibitors of Glycine Transporters. Łątka K, Bajda M. Int J Mol Sci 23 8050 (2022)
  169. Assessment of Paroxetine Molecular Interactions with Selected Monoamine and γ-Aminobutyric Acid Transporters. Kowalska M, Fijałkowski Ł, Nowaczyk A. Int J Mol Sci 22 6293 (2021)
  170. Binding Mode of Human Norepinephrine Transporter Interacting with HIV-1 Tat. Adeniran C, Yuan Y, Davis SE, Lin C, Xu J, Zhu J, Zhan CG. ACS Chem Neurosci 12 1519-1527 (2021)
  171. Dynamic extracellular vestibule of human SERT: Unveiling druggable potential with high-affinity allosteric inhibitors. Salomon K, Abramyan AM, Plenge P, Wang L, Bundgaard C, Bang-Andersen B, Loland CJ, Shi L. Proc Natl Acad Sci U S A 120 e2304089120 (2023)
  172. Engineering and purification of a thermostable, high-yield, variant of PfCRT, the Plasmodium falciparum chloroquine resistance transporter. Wright DJ, O'Reilly M, Tisi D. Protein Expr Purif 141 7-18 (2018)
  173. Exploring Substrate Binding in the Extracellular Vestibule of MhsT by Atomistic Simulations and Markov Models. Abramyan AM, Quick M, Xue C, Javitch JA, Shi L. J Chem Inf Model 58 1244-1252 (2018)
  174. Functional characterization of dopamine and norepinephrine transport across the apical and basal plasma membranes of the human placental syncytiotrophoblast. Horackova H, Karahoda R, Vachalova V, Turkova H, Abad C, Staud F. Sci Rep 12 11603 (2022)
  175. Identification of the potassium-binding site in serotonin transporter. Hellsberg E, Boytsov D, Chen Q, Niello M, Freissmuth M, Rudnick G, Zhang YW, Sandtner W, Forrest LR. Proc Natl Acad Sci U S A 121 e2319384121 (2024)
  176. Inhibitor mechanisms in the S1 binding site of the dopamine transporter defined by multi-site molecular tethering of photoactive cocaine analogs. Krout D, Pramod AB, Dahal RA, Tomlinson MJ, Sharma B, Foster JD, Zou MF, Boatang C, Newman AH, Lever JR, Vaughan RA, Henry LK. Biochem Pharmacol 142 204-215 (2017)
  177. Latch and trigger role for R445 in DAT transport explains molecular basis of DTDS. Reith MEA, Jones KT, Zhen J, Topiol S. Bioorg Med Chem Lett 28 470-475 (2018)
  178. Mass Spectrometry Metabolomics and Feature-Based Molecular Networking Reveals Population-Specific Chemistry in Some Species of the Sceletium Genus. Reddy K, Stander MA, Stafford GI, Makunga NP. Front Nutr 9 819753 (2022)
  179. Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters. Liu H, Wu Y, Li C, Tang Q, Zhang YW. Front Pharmacol 13 1018473 (2022)
  180. Non-conserved residues dictate dopamine transporter selectivity for the potent synthetic cathinone and psychostimulant MDPV. Steele TWE, Spires Z, Jones CB, Glennon RA, Dukat M, Eltit JM. Neuropharmacology 200 108820 (2021)
  181. Pharmacological Characterization of a Betaine/GABA Transporter 1 (BGT1) Inhibitor Displaying an Unusual Biphasic Inhibition Profile and Anti-seizure Effects. Lie MEK, Kickinger S, Skovgaard-Petersen J, Ecker GF, Clausen RP, Schousboe A, White HS, Wellendorph P. Neurochem Res 45 1551-1565 (2020)
  182. Rare Opportunities for Insights Into Serotonergic Contributions to Brain and Bowel Disorders: Studies of the SERT Ala56 Mouse. Stilley SE, Blakely RD. Front Cell Neurosci 15 677563 (2021)
  183. Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane. Nichols AL, Blumenfeld Z, Luebbert L, Knox HJ, Muthusamy AK, Marvin JS, Kim CH, Grant SN, Walton DP, Cohen BN, Hammar R, Looger L, Artursson P, Dougherty DA, Lester HA. J Neurosci 43 2222-2241 (2023)
  184. Synthesis, Docking, 3-D-Qsar, and Biological Assays of Novel Indole Derivatives Targeting Serotonin Transporter, Dopamine D2 Receptor, and Mao-A Enzyme: In the Pursuit for Potential Multitarget Directed Ligands. Cerda-Cavieres C, Quiroz G, Iturriaga-Vásquez P, Rodríguez-Lavado J, Alarcón-Espósito J, Saitz C, Pessoa-Mahana CD, Chung H, Araya-Maturana R, Mella-Raipán J, Cabezas D, Ojeda-Gómez C, Reyes-Parada M, Pessoa-Mahana H. Molecules 25 E4614 (2020)
  185. The Lepidopteran KAAT1 and CAATCH1: Orthologs to Understand Structure-Function Relationships in Mammalian SLC6 Transporters. Castagna M, Cinquetti R, Verri T, Vacca F, Giovanola M, Barca A, Romanazzi T, Roseti C, Galli A, Bossi E. Neurochem Res 47 111-126 (2022)
  186. A mechanism of uncompetitive inhibition of the serotonin transporter. Bhat S, El-Kasaby A, Kasture A, Boytsov D, Reichelt JB, Hummel T, Sucic S, Pifl C, Freissmuth M, Sandtner W. Elife 12 e82641 (2023)
  187. Analysis of Different Binding Modes for Tiagabine within the GAT-1 Transporter. Łątka K, Bajda M. Biomolecules 12 1663 (2022)
  188. Chirality Matters: Fine-Tuning of Novel Monoamine Reuptake Inhibitors Selectivity through Manipulation of Stereochemistry. Kalaba P, Pacher K, Neill PJ, Dragacevic V, Zehl M, Wackerlig J, Kirchhofer M, Sartori SB, Gstach H, Kouhnavardi S, Fabisikova A, Pillwein M, Monje-Quiroga F, Ebner K, Prado-Roller A, Singewald N, Urban E, Langer T, Pifl C, Lubec J, Leban JJ, Lubec G. Biomolecules 13 1415 (2023)
  189. Clickable photoaffinity ligands for the human serotonin transporter based on the selective serotonin reuptake inhibitor (S)-citalopram. Yarravarapu N, Geffert L, Surratt CK, Cascio M, Lapinsky DJ. Bioorg Med Chem Lett 28 3431-3435 (2018)
  190. Dimerization and antidepressant recognition at noradrenaline transporter. Zhang H, Yin YL, Dai A, Zhang T, Zhang C, Wu C, Hu W, He X, Pan B, Jin S, Yuan Q, Wang MW, Yang D, Xu HE, Jiang Y. Nature 630 247-254 (2024)
  191. Experimental and Bioinformatic Insights into the Effects of Epileptogenic Variants on the Function and Trafficking of the GABA Transporter GAT-1. Piniella D, Canseco A, Vidal S, Xiol C, Díaz de Bustamante A, Martí-Carrera I, Armstrong J, Bastolla U, Zafra F. Int J Mol Sci 24 955 (2023)
  192. Extracellular loops matter - subcellular location and function of the lysine transporter Lyp1 from Saccharomyces cerevisiae. Van't Klooster JS, Bianchi F, Doorn RB, Lorenzon M, Lusseveld JH, Punter CM, Poolman B. FEBS J 287 4401-4414 (2020)
  193. Forty Four Years With Baruch Kanner and The Chloride Ion. Rudnick G. Neurochem Res 47 3-8 (2022)
  194. Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities. Djikic T, Martí Y, Spyrakis F, Lau T, Benedetti P, Davey G, Schloss P, Yelekci K. J Biomol Struct Dyn 37 291-306 (2019)
  195. Identification and characterization of the Fasciola hepatica sodium- and chloride-dependent taurine transporter. Hamali B, Pichler S, Wischnitzki E, Schicker K, Burger M, Holy M, Jaentsch K, Molin M, Sehr EM, Kudlacek O, Freissmuth M. PLoS Negl Trop Dis 12 e0006428 (2018)
  196. Induced fit, ensemble binding space docking and Monte Carlo simulations of MDMA 'ecstasy' and 3D pharmacophore design of MDMA derivatives on the human serotonin transporter (hSERT). Islas ÁA, Moreno LG, Scior T. Heliyon 7 e07784 (2021)
  197. Modulation of Glycinergic Neurotransmission may Contribute to the Analgesic Effects of Propacetamol. Barsch L, Werdehausen R, Leffler A, Eulenburg V. Biomolecules 11 493 (2021)
  198. Probing binding and occlusion of substrate in the human creatine transporter-1 by computation and mutagenesis. Clarke A, Farr CV, El-Kasaby A, Szöllősi D, Freissmuth M, Sucic S, Stockner T. Protein Sci 33 e4842 (2024)
  199. Reshaping the Binding Pocket of the Neurotransmitter:Solute Symporter (NSS) Family Transporter SLC6A14 (ATB0,+) Selectively Reduces Access for Cationic Amino Acids and Derivatives. Anderson CMH, Edwards N, Watson AK, Althaus M, Thwaites DT. Biomolecules 12 1404 (2022)
  200. Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543. Benito-Muñoz C, Perona A, Felipe R, Pérez-Siles G, Núñez E, Aragón C, López-Corcuera B. ACS Chem Neurosci 12 1860-1872 (2021)
  201. Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors. Paudel S, Kim E, Zhu A, Acharya S, Min X, Cheon SH, Kim KM. Biomol Ther (Seoul) 29 392-398 (2021)
  202. Structure and function of the SIT1 proline transporter in complex with the COVID-19 receptor ACE2. Li HZ, Pike ACW, Lotsaris I, Chi G, Hansen JS, Lee SC, Rödström KEJ, Bushell SR, Speedman D, Evans A, Wang D, He D, Shrestha L, Nasrallah C, Burgess-Brown NA, Vandenberg RJ, Dafforn TR, Carpenter EP, Sauer DB. Nat Commun 15 5503 (2024)
  203. Structure of cytosine transport protein CodB provides insight into nucleobase-cation symporter 1 mechanism. Hatton CE, Brotherton DH, Spencer M, Cameron AD. EMBO J 41 e110527 (2022)
  204. Structure-Based Modeling of Sigma 1 Receptor Interactions with Ligands and Cholesterol and Implications for Its Biological Function. Kim M, Bezprozvanny I. Int J Mol Sci 24 12980 (2023)
  205. Threonine 67 is a key component in the coupling of the NSS amino acid transporter KAAT1. Giovanola M, Vollero A, Cinquetti R, Bossi E, Forrest LR, Di Cairano ES, Castagna M. Biochim Biophys Acta Biomembr 1860 1179-1186 (2018)
  206. Transfer of stabilising mutations between different secondary active transporter families. Cecchetti C, Scull NJ, Mohan TC, Alguel Y, Jones AMC, Cameron AD, Byrne B. FEBS Open Bio 11 1685-1694 (2021)
  207. X-ray structure based evaluation of analogs of citalopram: Compounds with increased affinity and selectivity compared with R-citalopram for the allosteric site (S2) on hSERT. Topiol S, Bang-Andersen B, Sanchez C, Plenge P, Loland CJ, Juhl K, Larsen K, Bregnedal P, Bøgesø KP. Bioorg Med Chem Lett 27 470-478 (2017)
  208. In silico off-target profiling for enhanced drug safety assessment. Liu J, Gui Y, Rao J, Sun J, Wang G, Ren Q, Qu N, Niu B, Chen Z, Sheng X, Wang Y, Zheng M, Li X. Acta Pharm Sin B 14 2927-2941 (2024)
  209. A Novel Biotinylated Homotryptamine Derivative for Quantum Dot Imaging of Serotonin Transporter in Live Cells. Tomlinson ID, Kovtun O, Torres R, Bellocchio LG, Josephs T, Rosenthal SJ. Front Cell Neurosci 15 667044 (2021)
  210. Allosteric Binding of MDMA to the Human Serotonin Transporter (hSERT) via Ensemble Binding Space Analysis with ΔG Calculations, Induced Fit Docking and Monte Carlo Simulations. Islas ÁA, Scior T. Molecules 27 2977 (2022)
  211. Allosteric modulators of solute carrier function: a theoretical framework. Boytsov D, Schicker K, Hellsberg E, Freissmuth M, Sandtner W. Front Physiol 14 1166450 (2023)
  212. Anti-oxidant and neuro-modulatory effects of bioactive Byttneria pilosa leaf extract in swiss albino mice using behavioral models. Jyoti MA, Shah MS, Uddin MN, Hossain MK, Han A, Geng P, Islam MN, Mamun AA. Front Chem 12 1341308 (2024)
  213. Aromatic Bromination Abolishes the Psychomotor Features and Pro-social Responses of MDMA ("Ecstasy") in Rats and Preserves Affinity for the Serotonin Transporter (SERT). Sáez-Briones P, Castro-Castillo V, Díaz-Véliz G, Valladares L, Barra R, Hernández A, Cassels BK. Front Pharmacol 10 157 (2019)
  214. Biochemical and Pharmacological aspects of Ganoderma lucidum: Exponent from the in vivo and computational investigations. Hossen SMM, Yusuf ATM, Emon NU, Alam N, Sami SA, Polash SH, Nur MA, Mitra S, Uddin MH, Emran TB. Biochem Biophys Rep 32 101371 (2022)
  215. Characterizing the Specific Recognition of Xanthurenic Acid by GEP1 and GEP1-GCα Interactions in cGMP Signaling Pathway in Gametogenesis of Malaria Parasites. Zhu C, Liang X, Chen X, Liang M, Zheng J, Wan B, Luo S. Int J Mol Sci 24 2561 (2023)
  216. Chemical profiles and pharmacological attributes of Apis cerana indica beehives using combined experimental and computer-aided studies. Tareq AM, Hossain MM, Uddin M, Islam F, Khan Z, Karim MM, Lyzu C, Ağagündüz D, Reza ASMA, Emran TB, Capasso R. Heliyon 9 e15016 (2023)
  217. Combined In Silico, Ex Vivo, and In Vivo Assessment of L-17, a Thiadiazine Derivative with Putative Neuro- and Cardioprotective and Antidepressant Effects. Sarapultsev A, Vassiliev P, Grinchii D, Kiss A, Mach M, Osacka J, Balloova A, Paliokha R, Kochetkov A, Sidorova L, Sarapultsev P, Chupakhin O, Rantsev M, Spasov A, Dremencov E. Int J Mol Sci 22 13626 (2021)
  218. Cross-Linking and Functional Analyses for Dimerization of a Cysteine Mutant of Glycine Transporter 1. Wang J, Liu H, Zhang YW. Int J Mol Sci 23 16157 (2022)
  219. Cryo-EM structure of the dopamine transporter with a novel atypical non-competitive inhibitor bound to the orthosteric site. Pedersen CN, Yang F, Ita S, Xu Y, Akunuri R, Trampari S, Neumann CMT, Desdorf LM, Schiøtt B, Salvino JM, Mortensen OV, Nissen P, Shahsavar A. J Neurochem 168 2043-2055 (2024)
  220. Effects of serta and sertb knockout on aggression in zebrafish (Danio rerio). Tea M, Pan YK, Lister JGR, Perry SF, Gilmour KM. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 210 785-799 (2024)
  221. Evaluation of Neurotropic Activity and Molecular Docking Study of New Derivatives of pyrano[4″,3″:4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidines on the Basis of pyrano[3,4-c]pyridines. Dashyan SS, Babaev EV, Paronikyan EG, Ayvazyan AG, Paronikyan RG, Hunanyan LS. Molecules 27 3380 (2022)
  222. GABA transport cycle: beyond a GAT feeling. Shahsavar A, Wellendorph P. Nat Struct Mol Biol 30 863-865 (2023)
  223. Genome-Wide Identification, Characterization and Expression Analysis of the Solute Carrier 6 Gene Family in Silkworm (Bombyx mori). Tang X, Liu H, Chen Q, Wang X, Xiong Y, Zhao P. Int J Mol Sci 17 E1675 (2016)
  224. Identification of functional single nucleotide polymorphisms in the porcine SLC6A4 gene associated with aggressive behavior in weaned pigs after mixing. Guo Y, Zhao J, Xu Q, Gao S, Liu M, Zhang C, Schinckel AP, Zhou B. J Anim Sci 100 skac131 (2022)
  225. Identification of the benztropine analog [125I]GA II 34 binding site on the human dopamine transporter. Tomlinson MJ, Krout D, Pramod AB, Lever JR, Newman AH, Henry LK, Vaughan RA. Neurochem Int 123 34-45 (2019)
  226. Inclusion Scenarios and Conformational Flexibility of the SSRI Paroxetine as Perceived from Polymorphism of β-Cyclodextrin-Paroxetine Complex. Aree T. Pharmaceuticals (Basel) 15 98 (2022)
  227. Ligand coupling mechanism of the human serotonin transporter differentiates substrates from inhibitors. Gradisch R, Schlögl K, Lazzarin E, Niello M, Maier J, Mayer FP, Alves da Silva L, Skopec SMC, Blakely RD, Sitte HH, Mihovilovic MD, Stockner T. Nat Commun 15 417 (2024)
  228. Membrane cholesterol regulates inhibition and substrate transport by the glycine transporter, GlyT2. Frangos ZJ, Wilson KA, Aitken HM, Cantwell Chater R, Vandenberg RJ, O'Mara ML. Life Sci Alliance 6 e202201708 (2023)
  229. Molecular Modelling of Potential Candidates for the Treatment of Depression. Silva DR, Barigye SJ, Santos-Garcia L, Fontes Ferreira da Cunha E. Mol Inform 38 e1900024 (2019)
  230. Short-course antidepressant therapy reduces discontinuation syndrome while maintaining treatment efficacy in patients with refractory functional dyspepsia: A randomized controlled trial. Wang QQ, Cheng L, Wu BY, Xu P, Qiu HY, Wang B, Yan XJ, Chen SL. Front Psychiatry 13 1063722 (2022)
  231. Editorial Stereo-Psychopharmacology: The Case of Citalopram and Escitalopram. Ng I, Greenblatt HK, Greenblatt DJ. Clin Pharmacol Drug Dev 5 331-335 (2016)
  232. Structural biology: Antidepressants at work. Caron MG, Gether U. Nature 532 320-321 (2016)
  233. Structure of the human dopamine transporter and mechanisms of inhibition. Srivastava DK, Navratna V, Tosh DK, Chinn A, Sk MF, Tajkhorshid E, Jacobson KA, Gouaux E. Nature 632 672-677 (2024)
  234. 5-HT_FAsTR: a versatile, label-free, high-throughput, fluorescence-based microplate assay to quantify serotonin transport and release. Bukowski L, Strøm ME, Andersen JL, Maesen JB, Tian L, Sinning S. Sci Rep 14 6541 (2024)
  235. In silico analysis of a SLC6A4 G100V mutation in lung cancers. Pappula AL, Gibson LN, Bouley RA, Petreaca RC. MicroPubl Biol 2022 (2022)
  236. In silico structural studies on the vesicular neutral amino acid transporter NTT4 (SLC6A17). Kukułowicz J, Bajda M. Comput Struct Biotechnol J 23 3342-3347 (2024)
  237. A Conserved Intramolecular Ion-Pair Plays a Critical but Divergent Role in Regulation of Dimerization and Transport Function among the Monoamine Transporters. Chen S, Huang X, Zhang X, Li C, Zhang YW. Int J Mol Sci 25 4032 (2024)
  238. Allosteric modulation of serotonin and dopamine transporters: New insights from computations and experiments. Nguyen H, Cheng MH, Lee JY, Aggarwal S, Mortensen OV, Bahar I. Curr Res Physiol 7 100125 (2024)
  239. Alternating access of a bacterial homolog of neurotransmitter: sodium symporters determined from AlphaFold2 ensembles and DEER spectroscopy. Schwartz AC, Stein RA, Gil-Iturbe E, Quick M, Mchaourab HS. Proc Natl Acad Sci U S A 121 e2406063121 (2024)
  240. Antidepressant fluoxetine alleviates colitis by reshaping intestinal microenvironment. Teng S, Yang Y, Zhang W, Li X, Li W, Cui Z, Min L, Wu J. Cell Commun Signal 22 176 (2024)
  241. Bioisosteric analogs of MDMA: Improving the pharmacological profile? Alberto-Silva AS, Hemmer S, Bock HA, da Silva LA, Scott KR, Kastner N, Bhatt M, Niello M, Jäntsch K, Kudlacek O, Bossi E, Stockner T, Meyer MR, McCorvy JD, Brandt SD, Kavanagh P, Sitte HH. J Neurochem 168 2022-2042 (2024)
  242. Deciphering the Pharmacological Potentials of Methanol Extract of Sterculia foetida Seeds Using Experimental and Computational Approaches. Alam N, Banu N, Alam NU, Ruman U, Khan Z, Ibn Aziz MA, Barua N, Chy FJ, Jahan A, Juthy TS, Nassan MA, El-Bahy SM, Abdel-Rahman Mohamed A, Sayeed MA, Emran TB. Evid Based Complement Alternat Med 2022 3403086 (2022)
  243. Design, Synthesis, and Functional Evaluation of 1, 5-Disubstituted Tetrazoles as Monoamine Neurotransmitter Reuptake Inhibitors. Paudel S, Wang S, Kim E, Kundu D, Min X, Shin CY, Kim KM. Biomol Ther (Seoul) 30 191-202 (2022)
  244. Exploring the sedative properties of natural molecules from hop cones (Humulus lupulus) as promising natural anxiolytics through GABA receptors and the human serotonin transporter. Belal A, Elballal MS, Al-Karmalawy AA, Hassan AHE, Roh EJ, Ghoneim MM, Ali MAM, Obaidullah AJ, Alotaibi JM, Shaaban S, Elanany MA. Front Chem 12 1425485 (2024)
  245. Fluorescence-Detection Size-Exclusion Chromatography-Based Thermostability Assay for Membrane Proteins. Yao H, Cai H, Li D. Methods Mol Biol 2564 299-315 (2023)
  246. Fluoxetine treatment during the postpartal period may have short-term impacts on murine maternal skeletal physiology. Fricke HP, Krajco CJ, Perry MJ, Brettingen LJ, Wake LA, Charles JF, Hernandez LL. Front Pharmacol 14 1244580 (2023)
  247. In Silico Investigations into the Selectivity of Psychoactive and New Psychoactive Substances in Monoamine Transporters. Botha MJ, Kirton SB. ACS Omega 7 38311-38321 (2022)
  248. Mechanotransduction Ion Channels in Hearing and Touch. Li S, Yan Z. Adv Exp Med Biol 1349 371-385 (2021)
  249. Molecular basis of human noradrenaline transporter reuptake and inhibition. Tan J, Xiao Y, Kong F, Zhang X, Xu H, Zhu A, Liu Y, Lei J, Tian B, Yuan Y, Yan C. Nature 632 921-929 (2024)
  250. Molecular characterization of the serotonergic transporter from the cestode Echinococcus granulosus: pharmacology and potential role in the nervous system. Camicia F, Vaca HR, Guarnaschelli I, Koziol U, Mortensen OV, Fontana ACK. Parasitol Res 121 1329-1343 (2022)
  251. Neuropharmacological and antiproliferative activity of Tetrastigma leucostaphyllum (Dennst.) Alston: Evidence from in-vivo, in-vitro and in-silico approaches. Rudra S, Omar Faruque M, Tahamina A, Uddin Emon N, Khalil Al Haidar I, Bokhtear Uddin S. Saudi Pharm J 31 929-941 (2023)
  252. New Insight into Selective Serotonin Receptor Agonists in the Central Nervous System, Studied with WAY163909 in Obese and Diabetic Wistar Rats. Bogomilov I, Boyadjieva N, Nikolov R. Brain Sci 13 545 (2023)
  253. Response Surface Study on Molecular Docking Simulations of Citalopram and Donepezil as Potent CNS Drugs. Alikhani R, Ebadi A, Karami P, Shahbipour S, Razzaghi-Asl N. Iran J Pharm Res 20 560-576 (2021)
  254. Slc20a1 and Slc20a2 regulate neuronal plasticity and cognition independently of their phosphate transport ability. Ramos-Brossier M, Romeo-Guitart D, Lanté F, Boitez V, Mailliet F, Saha S, Rivagorda M, Siopi E, Nemazanyy I, Leroy C, Moriceau S, Beck-Cormier S, Codogno P, Buisson A, Beck L, Friedlander G, Oury F. Cell Death Dis 15 20 (2024)
  255. Structural Studies of the Taurine Transporter: A Potential Biological Target from the GABA Transporter Subfamily in Cancer Therapy. Stary D, Bajda M. Int J Mol Sci 25 7339 (2024)
  256. Structure of the human dopamine transporter in complex with cocaine. Nielsen JC, Salomon K, Kalenderoglou IE, Bargmeyer S, Pape T, Shahsavar A, Loland CJ. Nature 632 678-685 (2024)
  257. Structures of synaptic vesicle protein 2A and 2B bound to anticonvulsants. Mittal A, Martin MF, Levin EJ, Adams C, Yang M, Provins L, Hall A, Procter M, Ledecq M, Hillisch A, Wolff C, Gillard M, Horanyi PS, Coleman JA. Nat Struct Mol Biol (2024)
  258. News Structures of the dopamine transporter point to ways to target addiction and disease. Sitte HH. Nature 632 509-511 (2024)
  259. Substrate binding and inhibition mechanism of norepinephrine transporter. Ji W, Miao A, Liang K, Liu J, Qi Y, Zhou Y, Duan X, Sun J, Lai L, Wu JX. Nature 633 473-479 (2024)
  260. Synthesis of Novel Nicotinic Ligands with Multimodal Action: Targeting Acetylcholine α4β2, Dopamine and Serotonin Transporters. González-Gutiérrez JP, Pessoa-Mahana HA, Iturriaga-Vásquez PE, Reyes-Parada MI, Guerra-Díaz NE, Hodar-Salazar M, Viscarra F, Paillali P, Núñez-Vivanco G, Lorca-Carvajal MA, Mella-Raipán J, Zúñiga MC. Molecules 24 E3808 (2019)
  261. Transport and inhibition mechanisms of the human noradrenaline transporter. Hu T, Yu Z, Zhao J, Meng Y, Salomon K, Bai Q, Wei Y, Zhang J, Xu S, Dai Q, Yu R, Yang B, Loland CJ, Zhao Y. Nature 632 930-937 (2024)
  262. Comment Transporter-protein structures show how salt gets a sweet ride into cells. Drew D. Nature 601 194-196 (2022)
  263. Unique Substrate Recognition and Sodium-Substrate Binding Stoichiometry in a Bacterial Serotonin Transporter, TuriSERT. Li M, Zhang X, Chen S, Liu H, Zhang YW. Int J Mol Sci 24 17112 (2023)
  264. Unveiling the crucial role of betaine: modulation of GABA homeostasis via SLC6A1 transporter (GAT1). Bhatt M, Lazzarin E, Alberto-Silva AS, Domingo G, Zerlotti R, Gradisch R, Bazzone A, Sitte HH, Stockner T, Bossi E. Cell Mol Life Sci 81 269 (2024)


Quick links